Protective Immunity and New Vaccines for Lyme Disease

Maria Gomes-Solecki; Paul M Arnaboldi; P Bryon Backenson; Jorge L Benach; Christopher L Cooper; Raymond J Dattwyler; Maria Diuk-Wasser; Erol Fikrig; J W Hovius; Will Laegreid; Urban Lundberg; Richard T Marconi; Adriana R Marques; Philip Molloy; Sukanya Narasimhan; Utpal Pal; Joao H F Pedra; Stanley Plotkin; Daniel L Rock; Patricia Rosa; Sam R Telford; Jean Tsao; X Frank Yang; Steven E Schutzer

doi:10.1093/cid/ciz872

Protective Immunity and New Vaccines for Lyme Disease

Clin Infect Dis. 2020 Apr 10;70(8):1768-1773. doi: 10.1093/cid/ciz872.

Authors

Maria Gomes-Solecki¹, Paul M Arnaboldi², P Bryon Backenson³, Jorge L Benach⁴, Christopher L Cooper⁵, Raymond J Dattwyler², Maria Diuk-Wasser⁶, Erol Fikrig⁷, J W Hovius⁸, Will Laegreid⁹, Urban Lundberg¹⁰, Richard T Marconi¹¹, Adriana R Marques¹², Philip Molloy¹³, Sukanya Narasimhan⁷, Utpal Pal¹⁴, Joao H F Pedra¹⁵, Stanley Plotkin¹⁶, Daniel L Rock¹⁷, Patricia Rosa¹⁸, Sam R Telford¹⁹, Jean Tsao^{20

21}, X Frank Yang²², Steven E Schutzer²³

Affiliations

¹ Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA.
² Department of Microbiology/Immunology, New York Medical College, New York, USA.
³ New York State Department of Health, Albany, New York, USA.
⁴ Department of Molecular Genetics and Microbiology, Stony Brook University, New York, USA.
⁵ Molecular and Translational Sciences, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
⁶ Department of Ecology, Evolution, and Environmental Biology, Columbia University, New York, USA.
⁷ Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
⁸ Department of Internal Medicine, Section of Infectious Diseases, Amsterdam Multidisciplinary Lyme Borreliosis Center, Amsterdam University Medical Centers, Academic Medical Center, The Netherlands.
⁹ Department of Veterinary Sciences, Wyoming State Veterinary Laboratory, University of Wyoming, Laramie, Wyoming, USA.
¹⁰ Valneva Austria GmbH, Vienna, Austria.
¹¹ Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.
¹² Lyme Disease Studies Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
¹³ Imugen, Norwood, Massachusetts, USA.
¹⁴ Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
¹⁵ Department of Microbiology and Immunology, University of Maryland School of Medicine, Maryland, USA.
¹⁶ Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁷ College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Illinois, USA.
¹⁸ Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
¹⁹ Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.
²⁰ Department of Fisheries and Wildlife, Michigan State University, East Lansing, Michigan, USA.
²¹ Departments of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, USA.
²² Department of Microbiology and Immunology, Indiana University of School of Medicine, Indianapolis, Indiana, USA.
²³ Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Abstract

Lyme disease, caused by some Borrelia burgdorferi sensu lato, is the most common tick-borne illness in the Northern Hemisphere and the number of cases, and geographic spread, continue to grow. Previously identified B. burgdorferi proteins, lipid immunogens, and live mutants lead the design of canonical vaccines aimed at disrupting infection in the host. Discovery of the mechanism of action of the first vaccine catalyzed the development of new strategies to control Lyme disease that bypassed direct vaccination of the human host. Thus, novel prevention concepts center on proteins produced by B. burgdorferi during tick transit and on tick proteins that mediate feeding and pathogen transmission. A burgeoning area of research is tick immunity as it can unlock mechanistic pathways that could be targeted for disruption. Studies that shed light on the mammalian immune pathways engaged during tick-transmitted B. burgdorferi infection would further development of vaccination strategies against Lyme disease.

Keywords: Borrelia burgdorferi; Borreliella; Lyme disease; vaccines.

Publication types

Clinical Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Borrelia burgdorferi*
Humans
Ixodes*
Lyme Disease* / prevention & control
Ticks*
Vaccination
Vaccines*

Substances

Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding